IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Navinés Ferrer, Arnau ^a   Serrano Candelas, Eva ^a   Molina Molina, Gustavo J ^a   Martín, Margarita ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; BISPECIFIC ANTIBODY; IMMUNOGLOBULIN E; LIGELIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; ANTI-IGE ANTIBODIES; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E RECEPTOR;

AIRWAY REMODELING; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; ATOPIC KERATOCONJUNCTIVITIS; BULLOUS PEMPHIGOID; CHRONIC DISEASE; CHRONIC URTICARIA; DRUG MECHANISM; FOOD ALLERGY; HUMAN; NOSE POLYP; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMIC MASTOCYTOSIS; IMMUNOLOGY; URTICARIA;

ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; IMMUNOGLOBULIN E; OFF-LABEL USE; OMALIZUMAB; RECEPTORS, IGE; URTICARIA;

EID: 85008625182     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/8163803     Document Type: Review

References (108)

1. H. C. Oettgen, "Fifty years later: emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases, " Journal of Allergy and Clinical Immunology, vol. 137, no. 6, pp. 1631-1645, 2016.
2. K. Asai, J. Kitaura, Y. Kawakami et al., "Regulation of mast cell survival by IgE, " Immunity, vol. 14, no. 6, pp. 791-800, 2001.
3. J. Kalesnikoff, M. Huber, V. Lam et al., "Monomeric IgE stimulates signaling pathways inmast cells that lead to cytokine production and cell survival, " Immunity, vol. 14, no. 6, pp. 801-811, 2001.
4. K. Ishizaka, "Basic mechanisms of IgE-mediated hypersensitivity, " Current Opinion in Immunology, vol. 1, no. 4, pp. 625-629, 1989.
5. K. S. Babu, R. Polosa, and J. B. Morjaria, "Anti-IgE-emerging opportunities for Omalizumab, " Expert Opinion on Biological Therapy, vol. 13, no. 5, pp. 765-777, 2013.
6. T. Zuberbier, W. Aberer, R. Asero et al., "The EAACI/ GA2LEN/EDF/WAOGuideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update, " Allergy, vol. 69, no. 7, pp. 868-887, 2014.
7. M. Mauro, C. Incorvaia, C. Formigoni, R. Elia, M. Russello, and D. Pellegrino, "The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology, " PanminervaMedica, vol. 54, no. 4, pp. 305-312, 2012.
8. C. Incorvaia, M. Mauro, M. Russello, C. Formigoni, G. G. Riario-Sforza, and E. Ridolo, "Omalizumab, an antiimmunoglobulin E antibody: state of the art, " Drug Design, Development andTherapy, vol. 8, pp. 197-207, 2014.
9. M. Desai and J. Oppenheimer, "Elucidating asthma phenotypes and endotypes: progress towards personalized medicine, " Annals of Allergy, Asthma & Immunology, vol. 116, no. 5, pp. 394-401, 2016.
10. J. Zhang, P. D. Paré, and A. J. Sandford, "Recent advances in asthma genetics, " Respiratory Research, vol. 9, article 4, 2008.
11. S. S. Braman, "The global burden of asthma, " Chest, vol. 130, supplement 1, pp. 4S-12S, 2006.
12. J. Corren, "Asthma phenotypes and endotypes: An evolving paradigm for classification, " Discovery Medicine, vol. 15, no. 83, pp. 243-249, 2013.
13. S. E. Wenzel, "Asthma phenotypes: The evolution from clinical to molecular approaches, " Nature Medicine, vol. 18, no. 5, pp. 716-725, 2012.
14. T. S. Hallstrand, M. W. Moody, M. L. Aitken, and W. R. Henderson Jr., "Airway immunopathology of asthma with exercise-induced bronchoconstriction, " The Journal of Allergy and Clinical Immunology, vol. 116, no. 3, pp. 586-593, 2005.
15. C. Miranda, A. Busacker, S. Balzar, J. Trudeau, and S. E. Wenzel, "Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation, " Journal of Allergy and Clinical Immunology, vol. 113, no. 1, pp. 101-108, 2004.
16. P. G. Woodruff, B. Modrek, D. F. Choy et al., "T-helper type 2-driven inflammation defines major subphenotypes of asthma, " American Journal of Respiratory and Critical CareMedicine, vol. 180, no. 5, pp. 388-395, 2009.
17. H. Bisgaard, K. Bonnelykke, P. M. A. Sleiman et al., "Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood, " American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 3, pp. 179-185, 2009.
18. B. N. Lambrecht, B. Salomon, D. Klatzmann, and R. A. Pauwels, "Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitizedmice, " The Journal of Immunology, vol. 160, no. 8, pp. 4090-4097, 1998.
19. L. S. van Rijt, S. Jung, A. KleinJan et al., "In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma, " Journal of Experimental Medicine, vol. 201, no. 6, pp. 981-991, 2005.
20. Z. Allakhverdi, M. R. Comeau, H. K. Jessup et al., "Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells, "The Journal of Experimental Medicine, vol. 204, no. 2, pp. 253-258, 2007.
21. T. Eiwegger and C. A. Akdis, "IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma, " European Journal of Immunology, vol. 41, no. 6, pp. 1535-1538, 2011.
22. J. Reibman, Y. Hsu, L. C. Chen, B. Bleck, andT. Gordon, "Airway epithelial cells release MIP-3/CCL20 in response to cytokines and ambient particulate matter, " American Journal of RespiratoryCell andMolecular Biology, vol. 28, no. 6, pp. 648-654, 2003.
23. C. E. Brightling, P. Bradding, F. A. Symon, S. T. Holgate, A. J. Wardlaw, and I. D. Pavord, "Mast-cell infiltration of airway smooth muscle in asthma, "The New England Journal of Medicine, vol. 346, no. 22, pp. 1699-1705, 2002.
24. J. V. Fahy, "Type 2 inflammation in asthma-present in most, absent in many, " Nature Reviews Immunology, vol. 15, no. 1, pp. 57-65, 2015.
25. L. E. Cheng, B. M. Sullivan, L. E. Retana, C. D. C. C. D. C. Allen, H.-E. Liang, and R. M. Locksley, "IgE-activated basophils regulate eosinophil tissue entry by modulating endothelial function, " Journal of Experimental Medicine, vol. 212, no. 4, pp. 513-524, 2015.
26. D. Voehringer, "Protective and pathological roles of mast cells and basophils, " Nature Reviews Immunology, vol. 13, no. 5, pp. 362-375, 2013.
27. S. Matsuzawa, K. Sakashita, T. Kinoshita, S. Ito, T. Yamashita, and K. Koike, "IL-9 enhances the growth of human mast cell progenitors under stimulationwith stemcell factor, "TheJournal of Immunology, vol. 170, no. 7, pp. 3461-3467, 2003.
28. R. P. Schleimer, S. A. Sterbinsky, J. Kaiser et al., "IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1, " The Journal of Immunology, vol. 148, no. 4, pp. 1086-1092, 1992.
29. P. D. Collins, S. Marleau, D. A. Griffiths-Johnson, P. J. Jose, and T. J. Williams, "Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo, " Journal of Experimental Medicine, vol. 182, no. 4, pp. 1169-1174, 1995.
30. S. Ying, Q. Meng, K. Zeibecoglouet al., "Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics, " Journal of Immunology, vol. 163, no. 11, pp. 6321-6329, 1999.
31. L. Benayoun, A. Druilhe, M.-C. Dombret, M. Aubier, and M. Pretolani, "Airway structural alterations selectively associated with severe asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 10, pp. 1360-1368, 2003.
32. A. S. Cowburn, K. Sladek, J. Soja et al., "Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma, " The Journal of Clinical Investigation, vol. 101, no. 4, pp. 834-846, 1998.
33. L. Hellgren, "The prevalence of urticaria in the total population, " Acta allergologica, vol. 27, no. 3, pp. 236-240, 1972.
34. T. Zuberbier, M. Balke, M. Worm, G. Edenharter, andM. Maurer, "Epidemiology of urticaria: A representative cross-sectional population survey, " Clinical and ExperimentalDermatology, vol. 35, no. 8, pp. 869-873, 2010.
35. A. L. Schocket, "Chronic urticaria: pathophysiology and etiology, or the what and why, " Allergy and Asthma Proceedings, vol. 27, no. 2, pp. 90-95, 2006.
36. R. A. Sabroe, E. Fiebiger, D. M. Francis et al., "Classification of anti-FcRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity, " Journal of Allergy and Clinical Immunology, vol. 110, no. 3, pp. 492-499, 2002.
37. L. P. Viegas, M. B. Ferreira, and A. P. Kaplan, "The maddening itch: An approach to chronic urticaria, " Journal of Investigational Allergology and Clinical Immunology, vol. 24, no. 1, pp. 1-5, 2014.
38. C. E. H. Grattan, T. B. Wallington, R. P. Warin, C. T. Kennedy, and J. W. Bradfield, "A serological mediator in chronic idiopathic urticaria-a clinical, immunological and histological evaluation, " British Journal of Dermatology, vol. 114, no. 5, pp. 583-590, 1986.
39. A. T. Khalaf, W. Li, and T. Jinquan, "Current advances in the management of urticaria, " ArchivumImmunologiae etTherapiae Experimentalis, vol. 56, no. 2, pp. 103-114, 2008.
40. A. P. Kaplan and M. Greaves, "Pathogenesis of chronic urticaria, " Clinical and Experimental Allergy, vol. 39, no. 6, pp. 777-787, 2009.
41. E. Fiebiger, F. Hammerschmid, G. Stingl, and D. Maurer, "Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship, " The Journal of Clinical Investigation, vol. 101, no. 1, pp. 243-251, 1998.
42. M. Ferrer, K. Nakazawa, and A. R. Kaplan, "Complement dependence of histamine release in chronic urticaria, " Journal of Allergy and Clinical Immunology, vol. 104, no. 1, pp. 169-172, 1999.
43. G. N. Konstantinou, R. Asero, M. Maurer, R. A. Sabroe, P. Schmid-Grendelmeier, and C. E. H. Grattan, "EAACI/GA2LEN task force consensus report: The autologous serum skin test in urticaria, " Allergy: European Journal of Allergy and Clinical Immunology, vol. 64, no. 9, pp. 1256-1268, 2009.
44. L. C. Presta, S. J. Lahr, R. L. Shields et al., "Humanization of an antibody directed against IgE, "The Journal of Immunology, vol. 151, no. 5, pp. 2623-2632, 1993.
45. L. Zheng, B. Li, W. Qian et al., "Fine epitopemapping of humanized anti-IgE monoclonal antibody omalizumab, " Biochemical and Biophysical Research Communications, vol. 375, no. 4, pp. 619-622, 2008.
46. A. Eggel, G. Baravalle, G. Hobi et al., "Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells, " The Journal of Allergy and Clinical Immunology, vol. 133, no. 6, pp. 1709-1719. e8, 2014.
47. E. Serrano-Candelas, R. Martinez-Aranguren, A. Valero et al., "Comparable actions of omalizumab on mast cells and basophils, " Clinical and Experimental Allergy, vol. 46, no. 1, pp. 92-102, 2016.
48. L. A. Beck, G. V. Marcotte, D. MacGlashan Jr., A. Togias, and S. Saini, "Omalizumab-induced reductions in mast cell FcRI expression and function, " The Journal of Allergy and Clinical Immunology, vol. 114, no. 3, pp. 527-530, 2004.
49. D. MacGlashan Jr., L. M. Lichtenstein, J. McKenzie-White et al., "Upregulation of FcRI on human basophils by IgE antibody is mediated by interaction of IgE with FcRI, " Journal of Allergy and Clinical Immunology, vol. 104, no. 2, part 1, pp. 492-498, 1999.
50. S. Kubo, K. Matsuoka, C. Taya et al., "Drastic up-regulation of FcRI on mast cells is induced by IgE binding through stabilization and accumulation of FcRI on the cell surface, " The Journal of Immunology, vol. 167, no. 6, pp. 3427-3434, 2001.
51. C. Prussin, D. T. Griffith, K. M. Boesel, H. Lin, B. Foster, and T. B. Casale, "Omalizumab treatment downregulates dendritic cell FcRI expression, " The Journal of Allergy and Clinical Immunology, vol. 112, no. 6, pp. 1147-1154, 2003.
52. T. W. Chang, "The pharmacological basis of anti-IgE therapy, " Nature Biotechnology, vol. 18, no. 2, pp. 157-162, 2000.
53. M. A. Chan, N. M. Gigliotti, A. L. Dotson, andL. J. Rosenwasser, "Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells, " Clinical and Translational Allergy, vol. 3, article 29, 2013.
54. O. Noga, G. Hanf, I. Brachmann et al., "Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma, " Journal of Allergy and Clinical Immunology, vol. 117, no. 6, pp. 1493-1499, 2006.
55. R. Skiepko, Z. Zietkowski, M. Lukaszyk et al., "Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation, " Postepy Dermatologii i Alergologii, vol. 31, no. 5, pp. 305-309, 2014.
56. K. F. Chung, S. E. Wenzel, J. L. Brozek et al., "International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, " The European Respiratory Journal, vol. 43, no. 2, pp. 343-373, 2014.
57. C.-Y. Lo, C. Michaeloudes, P. K. Bhavsar et al., "Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma, "The Journal of Allergy and Clinical Immunology, vol. 135, no. 5, pp. 1186-1195. e6, 2015.
58. S. Walker, M. Monteil, K. Phelan, T. J. Lasserson, and E. H. Walters, "Anti-IgE for chronic asthma in adults and children, " The Cochrane Database of Systematic Reviews, no. 2, Article ID CD003559, 2006.
59. G. Garcia, A. Magnan, R. Chiron et al., "A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma, " Chest, vol. 144, no. 2, pp. 411-419, 2013.
60. A. Nopp, S. G. O. Johansson, J. Adédoyin, J. Ankerst, M. Palmqvist, and H. Öman, "After 6 years with Xolair; a 3-year withdrawal follow-up, " Allergy: European Journal of Allergy and Clinical Immunology, vol. 65, no. 1, pp. 56-60, 2010.
61. M. Hoshino and J. Ohtawa, "Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma, " Respiration, vol. 83, no. 6, pp. 520-528, 2012.
62. A. P. Kaplan, "Therapy of chronic urticaria: A simple, modern approach, " Annals of Allergy, Asthma and Immunology, vol. 112, no. 5, pp. 419-425, 2014.
63. A. Kaplan, D. Ledford, M. Ashby et al., "Omalizumab inpatients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy, " Journal of Allergy and Clinical Immunology, vol. 132, no. 1, pp. 101-109, 2013.
64. M. Maurer, S. Altrichter, T. Bieber et al., "Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase, "The Journal of Allergy and Clinical Immunology, vol. 128, no. 1, pp. 202. e5-209. e5, 2011.
65. M. Maurer, K. Rosén, H. Hsieh et al., "Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria, " The New England Journal of Medicine, vol. 368, no. 10, pp. 924-35, 2013.
66. S. Saini, K. E. Rosen, H.-J. Hsieh et al., "A randomized, placebocontrolled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria, " Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 567-573. e1, 2011.
67. C. Bindslev-Jensen and P. S. Skov, "Efficacy of omalizumab in delayed pressure urticaria: A case report, " Allergy, vol. 65, no. 1, pp. 138-139, 2010.
68. J. A. Boyce, "Successful treatment of cold-induced urticaria/ anaphylaxis with anti-IgE, " Journal of Allergy and Clinical Immunology, vol. 117, no. 6, pp. 1415-1418, 2006.
69. O. Güzelbey, E. Ardelean, M. Magerl, T. Zuberbier, M. Maurer, and M. Metz, "Successful treatment of solar urticaria with anti-immunoglobulin E therapy, " Allergy: European Journal of Allergy and Clinical Immunology, vol. 63, no. 11, pp. 1563-1565, 2008.
70. K. Krause, E. Ardelean, B. Keãler et al., "Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy, " Allergy, vol. 65, no. 11, pp. 1494-1495, 2010.
71. M. Metz, P. Bergmann, T. Zuberbier, andM. Maurer, "Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy, " Allergy, vol. 63, no. 2, pp. 247-249, 2008.
72. J. Robyn and D. D. Metcalfe, "Systemic mastocytosis, " Advances in Immunology, vol. 89, pp. 169-243, 2006.
73. J. A. Douglass, K. Carroll, A. Voskamp, P. Bourke, A. Wei, and R. E. O'Hehir, "Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient, " Allergy, vol. 65, no. 7, pp. 926-927, 2010.
74. L. Kibsgaard, T. Skjold, M. Deleuran, and C. Vestergaard, "Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis, " Acta Dermato-Venereologica, vol. 94, no. 3, pp. 363-364, 2014.
75. G. Paraskevopoulos, E. Sifnaios, K. Christodoulopoulos, F. Mantopoulou, M. Papakonstantis, and D. Sabaziotis, "Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy, " European Annals of Allergy and Clinical Immunology, vol. 45, no. 2, pp. 52-55, 2013.
76. M. C. Carter, J. A. Robyn, P. B. Bressler, J. C. Walker, G. G. Shapiro, and D. D. Metcalfe, "Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis, " Journal of Allergy and Clinical Immunology, vol. 119, no. 6, pp. 1550-1551, 2007.
77. G. J. Molderings, M. Raithel, F. Kratz et al., "Omalizumab treatment of systemic mast cell activation disease: experiences from four cases, " Internal medicine, vol. 50, no. 6, pp. 611-615, 2011.
78. B. Belloni, M. Ziai, A. Lim et al., "Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels, " The Journal of Allergy and Clinical Immunology, vol. 120, no. 5, pp. 1223-1225, 2007.
79. L. Chularojanamontri, S. Wimoolchart, P. Tuchinda, K. Kulthanan, and N. Kiewjoy, "Role of omalizumab in a patientwith hyper-IgE syndrome and review dermatologic manifestations, " Asian Pacific Journal of Allergy and Immunology, vol. 27, no. 4, pp. 233-236, 2009.
80. K. D. Stone and C. Prussin, "Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases, " Clinical and Experimental Allergy, vol. 38, no. 12, pp. 1858-1865, 2008.
81. M. Humbert, L. P. Boulet, R. M. Niven, Z. Panahloo, M. Blogg, and G. Ayre, "Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis, " Allergy, vol. 64, no. 1, pp. 81-84, 2009.
82. J. Kuehr, J. Brauburger, S. Zielen et al., "Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis, " Journal of Allergy and Clinical Immunology, vol. 109, no. 2, pp. 274-280, 2002.
83. C. Bachert, P. Gevaert, P. Howarth, G. Holtappels, P. Van Cauwenberge, and S. G. O. Johansson, "IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma, " The Journal of Allergy and Clinical Immunology, vol. 111, no. 5, pp. 1131-1132, 2003.
84. P. Gevaert, L. Calus, T. Van Zele et al., "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma, " Journal of Allergy andClinical Immunology, vol. 131, no. 1, pp. 110. e1-116. e1, 2013.
85. M. D. C. Vennera, C. Picado, J. Mullol, I. Alobid, andM. Bernal-Sprekelsen, "Efficacy of omalizumab in the treatment of nasal polyps, " Thorax, vol. 66, no. 9, pp. 824-825, 2011.
86. S. Lehmann, C. Pfannenstiel, F. Friedrichs, K. KrÖger, N. Wagner, andK. Tenbrock, "Omalizumab: A newtreatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis, "Therapeutic Advances in Respiratory Disease, vol. 8, no. 5, pp. 141-149, 2014.
87. K. Tanou, E. Zintzaras, and A. G. Kaditis, "Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence, " Pediatric Pulmonology, vol. 49, no. 5, pp. 503-507, 2014.
88. J. Collins, G. de Vos, G. Hudes, and D. Rosenstreich, "Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab, " Journal of Asthma and Allergy, no. 5, pp. 65-70, 2012.
89. L. A. Pérez-de-Llano, M. C. Vennera, A. Parra et al., "Effects of omalizumab in Aspergillus-associated airway disease, " Thorax, vol. 66, no. 6, pp. 539-540, 2011.
90. C. Incorvaia, C. Pravettoni, M. Mauro, M.-R. Yacoub, F. Tarantini, and G. G. Riario-Sforza, "Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis, " Monaldi Archives for Chest Disease, vol. 69, no. 2, pp. 78-80, 2008.
91. L. E. Sheinkopf, A. W. Rafi, L. T. Do, R. M. Katz, and W. B. Klaustermeyer, "Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study, "Allergy and Asthma Proceedings, vol. 29, no. 5, pp. 530-537, 2008.
92. R. A. Krathen and S. Hsu, "Failure of omalizumab for treatment of severe adult atopic dermatitis, " Journal of the American Academy of Dermatology, vol. 53, no. 2, pp. 338-340, 2005.
93. C. Dufour, A. L. Souillet, C. Chaneliere et al., "Successful management of severe infant bullous pemphigoid with omalizumab, " British Journal of Dermatology, vol. 166, no. 5, pp. 1140-1142, 2012.
94. V. A. London, G. H. Kim, J. A. Fairley, and D. T. Woodley, "Successful treatment of bullous pemphigoid with omalizumab, " Archives of Dermatology, vol. 148, no. 11, pp. 1241-1243, 2012.
95. J. H. Savage, J.-P. Courneya, P. M. Sterba, D. W. Macglashan, S. S. Saini, and R. A. Wood, "Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy, " Journal of AllergyandClinical Immunology, vol. 130, no. 5, pp. 1123. e2-1129. e2, 2012.
96. K. C. Nadeau, L. C. Schneider, L. Hoyte, I. Borras, and D. T. Umetsu, "Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy, " The Journal of Allergy and Clinical Immunology, vol. 127, no. 6, pp. 1622-1624, 2011.
97. P. Bégin, T. Dominguez, S. P. Wilson et al., "Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods usingOmalizumab, " Allergy, Asthma andClinical Immunology, vol. 10, no. 1, article 7, 2014.
98. P. B. Williams and J. D. Sheppard Jr., "Omalizumab: A future innovation for treatment of severe ocular allergy" Expert Opinion on Biological Therapy, vol. 5, no. 12, pp. 1603-1609, 2005.
99. J.-B. Chen, P. C. Wu, A. F.-H. Hung et al., "Unique epitopes on CmX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells, " The Journal of Immunology, vol. 184, no. 4, pp. 1748-1756, 2010.
100. G. Pelaia, L. Gallelli, T. Renda et al., "Update on optimal use of omalizumab in management of asthma, " Journal of Asthma and Allergy, vol. 4, pp. 49-59, 2011.
101. J. M. Harris, R. Maciuca, M. S. Bradley et al., "A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma, " Respiratory Research, vol. 17, no. 1, p. 29, 2016.
102. J. M. Harris, C. R. Cabanski, H. Scheerens et al., "A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria, " The Journal of Allergy and Clinical Immunology, vol. 138, no. 6, pp. 1730-1732, 2016.
103. J. P. Arm, I. Bottoli, A. Skerjanec et al., "Pharmacokinetics, pharmacodynamics and safety ofQGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects, " Clinical & Experimental Allergy, vol. 44, no. 11, pp. 1371-1385, 2014.
104. S. W. Tam, S. Demissie, D. Thomas, andM. Däeron, "Abispecific antibody against human IgE and human FcRII that inhibits antigen-induced histamine release by human mast cells and basophils, " Allergy, vol. 59, no. 7, pp. 772-780, 2004.
105. D. Zhu, C. L. Kepley, M. Zhang, K. Zhang, and A. Saxon, "A novel humanimmunoglobulin Fc-Fc bifunctional fusion protein inhibits Fc RI-mediated degranulation, " Nature Medicine, vol. 8, no. 5, pp. 518-521, 2002.
106. A. Eggel, P. Buschor, M. J. Baumann, P. Amstutz, B. M. Stadler, and M. Vogel, "Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein, " Allergy: European Journal of Allergy and Clinical Immunology, vol. 66, no. 7, pp. 961-968, 2011.
107. B. Kim, A. Eggel, S. S. Tarchevskaya, M. Vogel, H. Prinz, andT. S. Jardetzky, "Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor, " Nature, vol. 491, no. 7425, pp. 613-617, 2012.
108. L. F. Pennington, S. Tarchevskaya, D. Brigger et al., "Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange, " Nature Communications, vol. 7, article 11610, 2016.